Inventor profile of:

John E. Bisi

City:

Apex, North Carolina

Country:

United States

Published Applications:

13

Last publication date:

2025-06-19

Top Assignees for applications by John E. Bisi

The entities that hold a legal rights for patent applications filed by inventor Bisi John E.:

Recent patent applications by Bisi John E.

John E. Bisi from Apex, US has applied for patents for these inventions. The list has both pending applications and granted patents:

#1 | 2025-06-19
US20250199015A1
Physics

CYCLIN-DEPENDENT KINASE 2 INHIBITORS FOR MEDICAL TREATMENT

#2 | 2023-08-03
US20230241059A1
Human necessities

ANTI-NEOPLASTIC COMBINATIONS AND DOSING REGIMENS USING CDK4/6 INHIBITOR COMPOUNDS TO TREAT RB-POSITIVE TUMORS

#3 | 2023-05-11
US20230146638A1
Human necessities

Treatment of EGFR-Driven Cancer with Fewer Side Effects

#4 | 2022-06-09
US20220175780A1
Human necessities

Treatment of Rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors

#5 | 2021-02-04
US20210030758A1
Human necessities

TREATMENT OF CANCERS HAVING DRIVING ONCOGENIC MUTATIONS

#6 | 2020-01-23
US20200022983A1
Human necessities

Treatment of Rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors

#7 | 2019-12-12
US20190374545A1
Human necessities

Treatment of EGFR-driven cancer with fewer side effects

#8 | 2019-05-23
US20190151311A1
Human necessities

Anti-neoplastic combinations and dosing regimens using CDK4/6 inhibitor compounds to treat Rb-positive tumors

#9 | 2019-01-31
US20190030034A1
Human necessities

Treatment of Rb-negative tumors using topoisomerase with cyclin dependent kinase 4/6 inhibitors

#10 | 2017-08-31
US20170246171A1
Human necessities

Treatment Of RB-Negative Tumors Using Topoisomerase Inhibitors In Combination With Cyclin Dependent Kinase 4/6 Inhibitors

#11 | 2017-06-29
US20170182043A1
Human necessities

Anti-neoplastic combinations and dosing regimens using CDK4/6 inhibitor compounds to treat RB-positive tumors

#12 | 2013-11-14
US20130303543A1
Human necessities

Protection of renal tissues from ischemia through inhibition of the proliferative kinases CDK4 and CDK6

#13 | 2011-09-15
US20110224227A1
Human necessities

HEMATOPOIETIC PROTECTION AGAINST CHEMOTHERAPEUTIC COMPOUNDS USING SELECTIVE CYCLIN-DEPENDENT KINASE 4/6 INHIBITORS

InventorID:

1914476 ⎘